Lytix Biopharma AS (STU:6BG) Short Interest


STU:6BG Lytix Biopharma AS STU:6BG
30 GF Score
Price €0.80
GF Value €0.01
! 2 Warning Signs
View Full Analysis

What is Lytix Biopharma AS Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:6BG vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Lytix Biopharma AS's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lytix Biopharma AS Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lytix Biopharma AS's Short Interest distribution charts can be found below:

* The bar in red indicates where Lytix Biopharma AS's Short Interest falls into.


STU:6BG
30GF Score
Lytix Biopharma AS STU:6BG
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lytix Biopharma AS (STU:6BG) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of €0.80 is trading 7940% above its estimated GF Value™ of €0.01.

Key valuation signals for STU:6BG:

  • Short Interest:
  • GF Value™: €0.01 vs. price of €0.80 (7940% above fair value)
  • GF Score™: 30/100 with 2 warning signs

No single metric tells the full story. See the STU:6BG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lytix Biopharma AS Business Description

Other Exchanges LYTIX:Norway
Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
30GF Score

Get the complete analysis for STU:6BG

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€0.01
GF Value